ES2196092T3 - Composicion antibacteriana liposomica, de baja rigidez. - Google Patents

Composicion antibacteriana liposomica, de baja rigidez.

Info

Publication number
ES2196092T3
ES2196092T3 ES95940928T ES95940928T ES2196092T3 ES 2196092 T3 ES2196092 T3 ES 2196092T3 ES 95940928 T ES95940928 T ES 95940928T ES 95940928 T ES95940928 T ES 95940928T ES 2196092 T3 ES2196092 T3 ES 2196092T3
Authority
ES
Spain
Prior art keywords
liposomic
low rigidity
antibacterial composition
agent
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95940928T
Other languages
English (en)
Inventor
Jacqueline Lagace
Christian Beaulac
Sebastien Clement-Major
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Montreal
Original Assignee
University of Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23430112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2196092(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Montreal filed Critical University of Montreal
Application granted granted Critical
Publication of ES2196092T3 publication Critical patent/ES2196092T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

LA INVENCION SE REFIERE A UNA FORMULACION LIPOSOMAL QUE CONTIENE AL MENOS UNA FORMULACION LIPOSOMAL QUE CONTIENE AL MENOS A UN AGENTE TERAPEUTICO TAL COMO UN ANTIBIOTICO Y A UN METODO PARA TRATAR INFECCIONES BACTERIANAS POR LA ADMINISTRACION DE TAL FORMULACION. SE PREVEN UNA FORMULACION LIPOSOMAL MULTILAMINAR CON POCA RIGIDEZ, LIBRE DE COLESTEROL, QUE INCLUYE UN LIPIDO NEUTRO Y AL MENOS UN AGENTE TERAPEUTICO CON LA QUE LA FORMULACION LIPOSOMAL MEJORA LA PENETRACION DEL AGENTE TERAPEUTICO EN EL INTERIOR DE LA CELULA BACTERIANA. UNA COMBINACION DE LIPIDO PREFERIDA ES DIPALMITOILFOSFATIDILCOLINA (DPPC):DIMIRISTOILFOSFATIDILGLICEROL (DMPG) EN UNA PROPORCION DE 10:1 A 15:1, CON UNA CONCENTRACION TOTAL DE LIPIDO DE ENTRE 5 Y 85 MM.
ES95940928T 1994-12-23 1995-12-22 Composicion antibacteriana liposomica, de baja rigidez. Expired - Lifetime ES2196092T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/363,416 US5662929A (en) 1994-12-23 1994-12-23 Therapeutic liposomal formulation

Publications (1)

Publication Number Publication Date
ES2196092T3 true ES2196092T3 (es) 2003-12-16

Family

ID=23430112

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95940928T Expired - Lifetime ES2196092T3 (es) 1994-12-23 1995-12-22 Composicion antibacteriana liposomica, de baja rigidez.

Country Status (14)

Country Link
US (1) US5662929A (es)
EP (1) EP0806941B1 (es)
JP (1) JP4523078B2 (es)
KR (1) KR100438657B1 (es)
AT (1) ATE235229T1 (es)
AU (1) AU702463B2 (es)
BR (2) BRPI9510423B8 (es)
CA (1) CA2206296C (es)
DE (1) DE69530124T2 (es)
DK (1) DK0806941T3 (es)
ES (1) ES2196092T3 (es)
NZ (1) NZ297364A (es)
PT (1) PT806941E (es)
WO (1) WO1996019972A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511477B2 (en) * 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6443949B2 (en) * 1997-03-13 2002-09-03 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6054133A (en) * 1997-07-10 2000-04-25 The Regents Of The University Of California Anti-microbial targeting for intracellular pathogens
US6613352B2 (en) * 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6365138B1 (en) * 2000-04-07 2002-04-02 The Regents Of The University Of California Compositions for metabolic protection and repair of lips
AU7548901A (en) * 2000-06-16 2002-01-02 Sloan Kettering Inst Cancer Liposomal encapsulation of chelated actinium-225 and uses thereof
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
DK2301524T3 (da) 2000-12-27 2013-07-15 Gilead Sciences Inc Inhalerbar aztreonam uden arginin til behandling og forebyggelse af bakterielle lungeinfektioner
AU2003230600B2 (en) * 2002-03-05 2009-06-04 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
DE10214983A1 (de) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
AU2003304204B2 (en) * 2002-10-29 2009-12-24 Insmed Incorporated Sustained release of antiinfectives
DE10255285A1 (de) * 2002-11-26 2004-06-03 Mcs Micro Carrier Systems Gmbh Selbst formende Phospholipid-Gele
EP1673074B1 (de) * 2003-10-15 2007-01-03 PARI GmbH Spezialisten für effektive Inhalation Flüssige zubereitung enthaltend tobramycin
WO2005044226A2 (en) * 2003-11-04 2005-05-19 Nectar Therapeutics Lipid formulations for spontaneous drug encapsulation
ES2798263T3 (es) 2005-12-08 2020-12-10 Insmed Inc Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
WO2013009761A1 (en) 2011-07-13 2013-01-17 The Foundry, Llc Methods and apparatus for delivering a therapeutic agent to nasopharyngeal mucosa targets
DE102009031274A1 (de) 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
MX384843B (es) 2014-05-15 2025-03-14 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
CN106999419A (zh) 2014-08-04 2017-08-01 佐尼奥尼制药股份有限公司 远程装载略微水溶性药物至脂质膜泡
ES2574615B1 (es) * 2014-12-19 2017-07-24 Biopraxis Research Aie Nanopartícula lipídica de tobramicina
JP2020536063A (ja) * 2017-10-02 2020-12-10 アリディス ファーマシューティカルズ インコーポレイティド 緑膿菌感染に対する組成物及び方法
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3787602A4 (en) 2018-05-02 2022-03-23 Insmed Incorporated PROCESS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS
CN117017999B (zh) * 2023-09-20 2024-11-12 四川大学 一种夫西地酸磷脂复合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
US4952405A (en) * 1988-10-20 1990-08-28 Liposome Technology, Inc. Method of treating M. avium infection
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
PT100486B (pt) * 1992-05-14 1999-07-30 Ineti Inst Nac Engenh E Tecnol Aminoglucosidos lipossomais com altas eficacia de encapsulacao e actividade terapeutica, nomeadamente a netilmicina, e processo para a sua preparcao
WO1994012155A1 (en) * 1992-12-02 1994-06-09 Vestar, Inc. Antibiotic formulation and process

Also Published As

Publication number Publication date
WO1996019972A1 (en) 1996-07-04
BRPI9510423B8 (pt) 2019-11-05
JP4523078B2 (ja) 2010-08-11
EP0806941A1 (en) 1997-11-19
PT806941E (pt) 2003-08-29
US5662929A (en) 1997-09-02
KR100438657B1 (ko) 2004-08-18
JPH10511363A (ja) 1998-11-04
EP0806941B1 (en) 2003-03-26
AU702463B2 (en) 1999-02-25
ATE235229T1 (de) 2003-04-15
DE69530124T2 (de) 2004-02-05
AU4251096A (en) 1996-07-19
NZ297364A (en) 2000-01-28
BR9510423A (pt) 2003-01-07
KR980700062A (ko) 1998-03-30
DE69530124D1 (de) 2003-04-30
CA2206296A1 (en) 1996-07-04
DK0806941T3 (da) 2003-07-21
MX9704679A (es) 1998-07-31
CA2206296C (en) 2007-05-22

Similar Documents

Publication Publication Date Title
PT806941E (pt) Composicoes anti-bacterianas liposomicas de rigidez baixa
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
AU2526095A (en) Transdermal device for administration through de-epithelialized skin
DE60134855D1 (de) Orale zubereitungen, die antimikrobielle wirkstoffe enthalten zur prävention von systemischen erkrankungen
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
EA199900553A1 (ru) Чрескожная терапевтическая система
ATE316794T1 (de) Pharmazeutische zusammensetzungen enthaltend lysostaphin allein oder in kombination mit einem antibiotikum zur behandlung von staphylokokkeninfektionen
NZ510690A (en) Methods for administration of antibiotics
EA200000594A1 (ru) Новые макролиды
DE60123277D1 (de) Makrolidantibiotika
BRPI9915480B8 (pt) azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos.
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
GEP20002332B (en) Cefalosporin Derivatives
AU3902299A (en) Methods of treating microbial infection and therapeutic formulations therefor
HUP0004579A2 (hu) Antibakteriális hatású, a 3'-N-pozícióban módosított szerkezetű 6-0-szubsztituált-eritromicin-ketolid-származékok és ezeket tartalmazó gyógyszerkészítmények
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
WO2000012049A3 (en) A method for the treatment of staphylococcal disease
KR950026524A (ko) 피부질환 치료용 의약조성물
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
ATE258375T1 (de) Behandlungen von der foulbroodbienenkrankheit
GR3004655T3 (es)
ES2169124T3 (es) Acido 4-aminomicofenolico 6-sustituido y derivados con actividad inmunosupresora.
Olay et al. Experimental Staphylococcus aureus osteomyelitis treated with fosfomycin and cephazolin: Single and combined therapy.
ES2086518T3 (es) Compuesto farmaceutico con accion cicatrizante.
WO1992018090A3 (en) Antimicrobial oral compositions